The development and implementation of pathological parameters and molecular testing impact prognosis of colorectal adenocarcinoma
Midie Xu(Shanghai Medical College of Fudan University), Weiqi Sheng(Shanghai Medical College of Fudan University), Hui‐Chuan Sun(Fudan University), Shujuan Ni(Shanghai Medical College of Fudan University), Junjie Peng(Fudan University Shanghai Cancer Center), Yingxue Liu(Mudanjiang Medical University), Changming Zhou(Shanghai Medical College of Fudan University), Xin Wang(Jiangsu University), Meng Zhang(Shanghai Medical College of Fudan University), Yaqi Li(Nanchang University), Xiaoyan Zhou(Shanghai Medical College of Fudan University), Weiwei Weng(Shanghai Medical College of Fudan University), Cong Tan(Shanghai Medical College of Fudan University), Xu Wang(Shanghai Medical College of Fudan University), Yu Yang(Shanghai Medical College of Fudan University), Dan Huang(Chinese PLA General Hospital), Lei Wang(Shanghai Jiao Tong University), Jinjia Chang(Fudan University Shanghai Cancer Center)
Cited by 4
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
|International Journal of Cancer|2009|979